Search

Displaying results 2701 - 2710 of 6951 in total
  1. Drug

    Tesamorelin

    go.drugbank.com/drugs/DB08869
    ApprovedInvestigational

    Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. … Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients

  2. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  3. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome). … [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single

  4. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.

  5. Drug

    Glycol salicylate

    go.drugbank.com/drugs/DB11323
    Approved

    This drug belongs to the _salicylate_ group of drugs, which are used as analgesic agents for the treatment of mild to moderate pain [L2691]. … It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain [L2686].

  6. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.

  7. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    [L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed … [A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting

  8. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  9. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

  10. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [L39292] In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular … [A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis.

    Products: RENACEPT